A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
LYDO is a multi-center study that will enroll approximately 1925 adult outpatients with
Attention Deficit/Hyperactivity Disorder (ADHD). Patients will receive, under open label
conditions, atomoxetine up to 100 mg/day during the acute, open-label part of the study.
Those patients that meet the response criteria will continue the blind phase of the study up
to a year. During that period, patients that respond to atomoxetine will be randomized to
continue the treatment with atomoxetine or with placebo (neither the patients nor
investigators know if patients receive atomoxetine or placebo).